Association between SD change in SHBG and 3-year diabetes risk, adjusted for age at randomization and Caucasian race
| HR | Lower 95% CI | Upper 95% CI | P value | |
| Placebo | ||||
| Males (SD=17.3) | 0.771 | 0.629 | 0.946 | 0.013 |
| Premenopausal (no hormone use) (SD=41.8) | 1.163 | 0.888 | 1.523 | 0.272 |
| Postmenopausal with no hormone use (SD=17.2) | 0.882 | 0.676 | 1.151 | 0.356 |
| Metformin | ||||
| Males (SD=20.1) | 0.836 | 0.677 | 1.034 | 0.099 |
| Premenopausal (no hormone use) (SD=40.8) | 0.949 | 0.710 | 1.269 | 0.725 |
| Postmenopausal with no hormone use (SD=23.0) | 1.614 | 1.046 | 2.491 | 0.030 |
| Intensive lifestyle intervention | ||||
| Males (SD=22.3) | 0.787 | 0.576 | 1.074 | 0.131 |
| Premenopausal (no hormone use) (SD=34.2) | 0.876 | 0.661 | 1.162 | 0.359 |
| Postmenopausal with no hormone use (SD=17.2) | 0.597 | 0.303 | 1.177 | 0.137 |
SHBG, sex hormone binding globulin.